UNSPSC 51171808: Difenidol or diphenidol

This classification denotes an antiemetic agent with the molecular formula C21H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NQO8R319LY, chemically known as 1,1-diphenyl-4-(1-piperidyl)butan-1-ol but generally known as difenidol, which bears US NIH Compound Identifier 3055. European Medicines Agency schedules Difenidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07121MIG.

The term DIFENIDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). DIFENIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Difenidol or diphenidol bears US NLM identifiers UMLS ID C0058371 and NCI Concept Code C65421. SMILES: C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O.

UNSPSC 51171808 Difenidol or diphenidol, a Commodity code, captures pharmaceutical products procured through state and local specimen collection, drug testing, pharmacy benefit, and generic multi-source pharmaceutical distribution programs. Recent solicitations show state and local agencies buying this and related pharmaceuticals for offender drug screening programs, state health benefit plan management, and cooperative purchasing networks that serve public agencies across multiple jurisdictions. The code reflects actual procurement activity centered on narcotics testing supplies, pharmacy benefit management services, and generic pharmaceutical products rather than the single-drug specificity the code name suggests.

State agencies dominate recent activity under this code. Collin County Community Supervision and Corrections Department posted RFP 2026-327 for offender specimen collection and drug testing services on July 9, 2026, with proposals due July 23, 2026, estimating $600,000 annually for approximately 25,031 tests using five- and six-panel immunoassay screening with LC/MS/MS or GC/MS confirmation across two sites in Plano and McKinney, with an anticipated award date of August 10, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026 (responses due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP posted January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to state and local government facilities in Minnesota and Oregon, with contract terms effective July 1, 2026. Recent activity concentrates in Texas and Minnesota; no other states appear in the current opportunities block.